BRAF-targeted therapy and immune responses to melanoma

Shin Foong Ngiow; Deborah A Knight; Antoni Ribas; Grant A McArthur; Mark J Smyth

doi:10.4161/onci.24462

BRAF-targeted therapy and immune responses to melanoma

Oncoimmunology. 2013 Jun 1;2(6):e24462. doi: 10.4161/onci.24462. Epub 2013 May 9.

Authors

Shin Foong Ngiow¹, Deborah A Knight, Antoni Ribas, Grant A McArthur, Mark J Smyth

Affiliation

¹ Immunology in Cancer and Infection Laboratory; Queensland Institute of Medical Research; Herston, QLD Australia ; Department of Pathology; University of Melbourne; Parkville, VIC Australia.

Abstract

Type I BRAF inhibitors and immunotherapy constitute two new exciting approaches for the treatment of advanced malignant melanoma. We have recently elucidated a role for host C-C chemokine receptor type 2 (CCR2) in the antineoplastic effects of type I BRAF inhibitors in mice, supporting the therapeutic potential of combining BRAF inhibitors with immunotherapy.

Keywords: BRAF; T cell; checkpoint; immunity; melanoma.

Publication types

Research Support, Non-U.S. Gov't